Aro Biotherapeutics Appoints Anthony Tolcher, MD, to Scientific Advisory Board

PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics announced the appointment of Anthony Tolcher, MD, to
its Scientific Advisory Board (SAB). Dr. Tolcher will provide strategic
counsel on the development of novel Centyrin therapeutic candidates for
oncology indications.

“We are excited and pleased to have Dr. Tolcher, a well-known leader in
translational oncology clinical research join Aro’s SAB,” said Sue
Dillon, PhD, Co-founder and Chief Executive Officer of Aro. “As we
progress our Centyrin pipeline toward initial clinical studies in
patients with cancer, Dr. Tolcher’s insights and experience will be
invaluable to us.”

Dr. Tolcher is the founder and CEO of NEXT-Oncology, a clinical research
organization dedicated to advancing highly innovative cancer
therapeutics to Phase I clinical trials. Before founding NEXT-Oncology,
Dr. Tolcher was co-founder and a leading member of START (South Texas
Accelerated Research Therapeutics), managing a network of clinical trial
centers across the U.S., Europe and Asia. He is a graduate of the
University of British Columbia in Vancouver, Canada. He performed his
residency in internal medicine at the University of Toronto, a
fellowship in oncology at the University of British Columbia and a
fellowship in research at the National Cancer Institute, Bethesda,
Maryland. Dr. Tolcher is a board certified medical oncologist.

Dr. Tolcher commented, “I am excited to work with Aro and its innovative
platform and help guide groundbreaking new therapeutics to the clinic.
The Centyrin technology has evolved with high quality science to provide
the potential for significantly differentiated drug candidates.”

Building a Pipeline of Life Changing Therapies

Centyrins are small, structurally simple, ultra-stable, highly soluble
proteins. These characteristics enable the discovery of medicines with
new mechanisms of action for cancer and other devastating diseases.
Aro’s lead program, which is a bi-specific Centyrin, is in late-stage
lead optimization for advanced non-small cell lung cancer. Aro’s second
therapeutic program is focused on creating a Centyrin-siRNA conjugate
for other forms of cancer. This first-of-its-kind combination is
designed to address unmet medical needs by targeting drug payloads in
high concentration to the site of disease, while lowering the toxicity
to non-target organs. The company holds an exclusive worldwide license
for research, development, manufacturing and commercialization of
Centyrin protein therapeutics.

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development
of a new generation of protein biologics called Centyrins. The company
is developing a wholly-owned pipeline of Centyrins for oncology and
immunology, and is working with leaders in the industry on leveraging
Centyrins for delivery of a variety of drug payloads, including nucleic
acid drugs for a diverse set of diseases. For more information, visit www.arobiotx.com.

Contacts

Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502